Cardiovascular Risk of Essential Hypertension: Influence of Class, Number, and Treatment-Time Regimen of Hypertension Medications

REFERENCES

• Almgren T, Persson B, Wilhelmsen L, Rosengren A, Andersson OK. (2005). Stroke and coronary heart disease in treated hypertension—a prospective cohort study over three decades. J. Intern. Med. 257:496–502.
   PubMed Web of Science ®Google Scholar
• Angeli A, Gatti G, Masera R. (1992). Chronobiology of the hypothalamic-pituitary-adrenal and renin-angiotensin-aldosterone systems. In Touitou Y, Haus E(eds.). Biologic rhythms in clinical and laboratory medicine. Berlin: Springer Verlag, 292–314.
   Google Scholar
• Asayama K, Ohkubo T, Yoshida S, Suzuki K, Metoli H, Harada A, Murakami Y, Ohashi Y, Ueshima H, Imai Y, the Japan Arteriosclerosis Longitudinal Study (JALS) group. (2009). Stroke risk and antihypertensive drug treatmnent in the general population: the Japan arteriosclerosis longitudinal study. J. Hypertens. 27:357–364.
   PubMed Web of Science ®Google Scholar
• Ayala DE, Hermida RC, Mojón A, Fernández JR. (2013). Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. Chronobiol. Int. 30: 340–352.
   Web of Science ®Google Scholar
• Bartter FC, Chan JCM, Simpson HW. (1979). Chronobiological aspect of plasma renin activity, plasma aldosterone and urinary electrolytes. In Krieger DT(ed.). Endocrine rhythms. New York: Raven, 49–132.
   Google Scholar
• Benetos A, Thomas F, Bean KE, Guize L. (2003). Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J. Hypertens. 21:1635–1640.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Rocella EJ. (2003). Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206–1252.
   PubMed Web of Science ®Google Scholar
• Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O'Brien E. (2003). Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N. Engl. J. Med. 348:2407–2415.
   PubMed Web of Science ®Google Scholar
• Crespo C, Aboy M, Fernández JR, Mojón A. (2012). Automatic identification of activity-rest periods based on actigraphy. Med. Biol. Eng. Comput. 50:329–340.
   PubMed Web of Science ®Google Scholar
• Crespo C, Fernández JR, Aboy M, Mojón A. (2013). Clinical application of a novel automatic algorithm for actigraphy-based activity and rest period identification to accurately determine awake and asleep ambulatory blood pressure parameters and cardiovascular risk. Chronobiol. Int. 30: 43–54.
   Web of Science ®Google Scholar
• Cugini P, Manconi E, Serdoz N, Mancini A, Meucci R, Scavo D. (1980). Rhythm characteristics of plasma renin, aldosterone and cortisol in five types of mesor-hypertension. J. Endocrinol. Invest. 3:143–149.
   PubMed Web of Science ®Google Scholar
• Cugini P, Letizia C, Scavo D. (1988). The circadian rhythmicity of serum angiotensin converting enzyme: its phasic relation with the circadian cycle of plasma renin and aldosterone. Chronobiologia 15:229–232.
   PubMedGoogle Scholar
• Eguchi K, Pickering TG, Hoshide S, Ishikawa J, Ishikawa S, Schwartz J, Shimada K, Kario K. (2008). Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. Am. J. Hypertens. 21:443–450.
   PubMed Web of Science ®Google Scholar
• Guidelines Committee. (2003). 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21:1011–1053.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Frauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. (2005). Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752.
   PubMed Web of Science ®Google Scholar
• Hermida RC. (1999). Time-qualified reference values for 24 h ambulatory blood pressure monitoring. Blood Press. Monit. 4:137–147.
   PubMedGoogle Scholar
• Hermida RC. (2007). Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study. Chronobiol. Int. 24:749–775.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE. (2003). Sampling requirements for ambulatory blood pressure monitoring in the diagnosis of hypertension in pregnancy. Hypertension 42:619–624.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE. (2009). Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 54:40–46.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Fernández JR. (1996). Computation of time-specified tolerance intervals for ambulatorily monitored blood pressure. Biomed. Instrum. Technol. 30:257–266.
   PubMedGoogle Scholar
• Hermida RC, Smolensky MH. (2004). Chronotherapy of hypertension. Curr. Opin. Nephrol. Hypertens. 13:501–505.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Mojón A, Fernández JR, Ayala DE. (1996). Computer-based medical system for the computation of blood pressure excess in the diagnosis of hypertension. Biomed. Instrum. Technol. 30:267–283.
   PubMedGoogle Scholar
• Hermida RC, Fernández JR, Mojón A, Ayala DE. (2000). Reproducibility of the hyperbaric index as a measure of blood pressure excess. Hypertension 35:118–125.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, Fernández JR, Ruilope LM, López JE. (2002a). Evaluation of the extent and duration of the “ABPM effect” in hypertensive patients. J. Am. Coll. Cardiol. 40:710–717.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Mojón A, Fernández JR, Alonso I, Ayala DE. (2002b). The tolerance-hyperbaric test: a chronobiologic approach for improved diagnosis of hypertension. Chronobiol. Int. 19:1183–1211.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Mojón A, López JE. (2003). Administration-time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 42:283–290.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Fontao MJ, López JE. (2004). Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. Chronobiol. Int. 21:277–296.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Calvo C. (2005a). Administration time-dependent effects of antihypertensive treatment on the circadian pattern of blood pressure. Curr. Opin. Nephrol. Hypertens. 14:453–459.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, Fernández JR, Covelo M, Mojón A, López JE. (2005b). Treatment of non-dipper hypertension with bedtime administration of valsartan. J. Hypertens. 23:1913–1922.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, Mojón A, Rodríguez M, Chayán L, López JE, Fontao MJ, Soler R, Fernández JR. (2005c). Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol. Int. 22:755–776.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Calvo C, Portaluppi F, Smolensky MH. (2007a). Chronotherapy of hypertension: administration-time dependent effects of treatment on the circadian pattern of blood pressure. Adv. Drug Deliv. Rev. 59:923–939.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Calvo C. (2007b). Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 50:715–722.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernandez JR, Mojón A, Calvo C. (2007c). Influence of measurement duration and frequency on ambulatory blood pressure monitoring. Rev. Esp. Cardiol. 60:131–138.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Portaluppi F. (2007d). Circadian variation of blood pressure: the basis for the chronotherapy of hypertension. Adv. Drug Deliv. Rev. 59:904–922.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, Lopez JE, Rodriguez M, Chayan L, Mojon A, Fontao MJ. Fernandez JR. (2007e). Dose- and administration-time-dependent effects of nifedipine GITS on ambulatory blood pressure in hypertensive subjects. Chronobiol. Int. 24:471–493.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Calvo C. (2008a). Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 51:69–76.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojon A, Fernandez JR. (2008b). Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Am. J. Hypertens. 21:948–954.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Chayán L, Mojón A, Fernández JR. (2009). Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol. Int. 26:61–79.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fontao MJ, Mojón A, Alonso I, Fernández JR. (2010a). Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiol. Int. 27:560–574.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. (2010b). Chronotherapy with valsartan/amlodipine combination in essential hypertension: improved blood pressure control with bedtime dosing. Chronobiol. Int. 27:1287–1303.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2010c). Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol. Int. 27:1629–1651.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2010d). Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. Am. J. Hypertens. 23:432–439.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Portaluppi F, Fabbian F, Smolensky MH. (2011a). Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am. J. Hypertens. 24:383–391.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2011b). Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J. Am. Coll. Cardiol. 58:1165–1173.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2011c). Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 34:1270–1276.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2011d). Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J. Am. Soc. Nephrol. 22:2313–2321.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fontao MJ, Fernández JR. (2011e). Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol. Int. 28:601–610.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2012a). Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am. J. Hypertens. 25:325–334.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2012b). Sleep-time blood pressure and the prognostic value of isolated-office and masked hypertension. Am. J. Hypertens. 25:297–305.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Mojón A. (2013a). Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction. Chronobiol. Int. 30: 68–86.
   Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Mojón A, Smolensky MH, Fabbian F, Portaluppi F. (2013b). Administration-time-differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol. Int. 30: 280–314.
   Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. (2013c). Ambulatory blood pressure monitoring: importance of sampling rate and duration—48 versus 24 hours—on the accurate assessment of cardiovascular risk. Chronobiol. Int. 30: 55–67.
   Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2013d). Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level—the “normotensive non-dipper” paradox. Chronobiol. Int. 30: 87–98.
   Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2013e). Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk. Chronobiol. Int. 30: 328–339.
   Web of Science ®Google Scholar
• Ibsen H. (2009). Antihypertensive treatment and risk of cardiovascular complications: is the cure worse than the disease? J. Hypertens. 27:221–223.
   PubMed Web of Science ®Google Scholar
• Katz F, Romfh P, Smith JA. (1975). Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man. J. Clin. Endocrinol. Metab. 40:125–134.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker HAJ, Zanchetti A. (2007). 2007 guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, Van Zwieten PA, Viigimaa M, Zanchetti. (2009). A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27:2121–2158.
   PubMed Web of Science ®Google Scholar
• Meng Y, Zhang Z, Liang X, Wu C, Qi G. (2010). Effects of combination therapy with amlodipine and fosinopril administered at different times on blood pressure and circadian blood pressure pattern in patients with essential hypertension. Acta Cardiol. 65:309–314.
   PubMed Web of Science ®Google Scholar
• Perloff D, Sokolow M, Cowan R. (1983). The prognostic value of ambulatory blood pressures. JAMA 249:2792–2798.
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Smolensky MH. (2000). Circadian rhythm and environmental determinants of blood pressure regulation in normal and hypertensive conditions. In White WB(ed.). Blood pressure monitoring in cardiovascular medicine and therapeutics. Totowa, NJ: Humana Press, 79–118.
   Google Scholar
• Portaluppi F, Smolensky MH. (2010). Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study. Chronobiol. Int. 27:1652–1667.
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol. Int. 27:1911–1929.
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Tiseo R, Smolensky MH, Hermida RC, Ayala DE, Fabbian F. (2012). Circadian rhythms and cardiovascular health. Sleep Med. Rev. 16:151–166.
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Muxfeldt ES. (2008). Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch. Intern. Med. 168:2340–2346.
   PubMed Web of Science ®Google Scholar
• Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J. (2003). Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J. Hypertens. 21:1291–1298.
   PubMed Web of Science ®Google Scholar
• Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F. (2010). Administration-time-dependent effect of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press. Monit. 15:173–180.
   PubMed Web of Science ®Google Scholar
• Smolensky MH, Siegel RA, Haus E, Hermida R, Portaluppi F. (2012). Biological rhythms, drug delivery, and chronotherapeutics. In Siepmann J, Siegel RA, Rathbone MJ(eds.). Fundamentals and applications of controlled release drug delivery. Heidelberg, Germany: Springer Verlag, 359–443.
   Google Scholar
• Tofé S, García B. (2009). 24-Hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J. Clin. Hypertens. (Greenwhich) 11:426–431.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistell M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. (1994). Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 24:793–801.
   PubMed Web of Science ®Google Scholar
• Zanchetti A. (2009). Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J. Hypertens. 27:1509–1520.
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Grassi G, Mancia G. (2009). When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J. Hypertens. 27:923–934.
   PubMed Web of Science ®Google Scholar